BRIEF-FDA Approves Niraparib And Abiraterone Acetate Plus Prednisone For Brca2-Mutated Metastatic Castration-Sensitive Prostate Cancer

Reuters
Dec 13
BRIEF-FDA Approves Niraparib And Abiraterone Acetate Plus Prednisone For Brca2-Mutated Metastatic Castration-Sensitive Prostate Cancer

Dec 12 (Reuters) - FDA:

  • FDA: APPROVES NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE FOR BRCA2-MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10